Randomized Trialhigh evidence
Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Nature medicine·May 22, 2026·PMID 42174253
Why it mattersMany patients experience inadequate weight loss or regain after bariatric surgery, yet effective adjunctive pharmacotherapy has been lacking. This trial provides high-quality evidence that semaglutide can safely and substantially augment weight loss in this challenging population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled